Should I buy CSL shares following this week's 6% slump?

What is all the commotion circling the CSL share price this week, and could it be a opportunity to add this giant to the portfolio?

| More on:
A scientist examining test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price was walloped yesterday following the release of a market update
  • Analysts weren't impressed by the forward guidance as donor fees remain elevated
  • Earnings are still projected to grow at a double-digit pace 

It was absolute bedlam for CSL Limited (ASX: CSL) shares yesterday following the release of a market update. A surprising upward revision in currency conversion impacts and a lower-than-expected FY24 guidance sent shivers down the spine of investors.

The Australian pharmaceutical giant was dealt a blow to its share price in response on Wednesday. At its deepest depth, the CSL share price reached a low of $282 during the session, equating to a fall of around 8.5%. Though, the market became more forgiving as the day went on, with the share price finishing at $287.25 as the closing bell rang out.

Now worth 6% less than it was at the beginning of the week, could the fall represent a favourable opportunity to buy CSL shares?

Hardly a business that is on life support

As covered by my colleague Bernd Struben, CSL is forecasting net profits after tax and amortisation (NPATA) of between US$2.9 billion and US$3.0 billion for FY24 on a constant currency basis.

This fell below what analysts had anticipated. However, given this would still represent an increase of between 13% to 18%, it sure could be worse. Some would argue that companies don't miss estimates; analysts miss reality.

Ultimately, a long-term shareholder should be more interested in the general direction of the business. Based on yesterday's update, the trend is still heading in the right direction, suggesting continued growth in earnings moving forward.

The bulk of concern is around higher donor fees required to source plasma for CSL Behring's therapies. This area of the business is responsible for around 63% of the company's total revenue, making it quite important.

On yesterday's investor call, CSL's chief financial officer Joy Linton commented on the fee pressure, stating:

Donor fees and labour costs have increased across the industry. Now COVID is receding, it is not a simple matter of just reducing donor fees. It is unlikely that donor fees will ever go back to pre-COVID levels.

Another pessimistic note was the mention of a generic rival for the company's Ferinject medicine. Added to its arsenal through the acquisition of Vifor, Ferinject now faces competition in 15 countries.

A potential substitute for CSL shares

The homegrown healthcare behemoth has remained popular among analysts up until yesterday's announcement.

Other articles published this month have revealed the upbeat view on CSL shared by Morgans, Market Matters, and Morgan Stanley — with one of the three holding a $339 price target on the company's shares.

Based on the latest guidance, CSL is now trading at around 31 times FY24 guided earnings. For a high-quality business with a diversified portfolio of products, that may not necessarily be expensive.

However, I have recently had my eyes on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) which is valued at 23 times FY24 consensus estimates. The US-based company makes money through the sale of its cystic fibrosis medicine, Trikafta.

Though, one could consider CSL shares a more defensive investment due to its broad range of treatments.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Vertex Pharmaceuticals. The Motley Fool Australia has recommended Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Woman on a swing at a beach, symbolising passive income.
Dividend Investing

Overinvested in Fortescue shares? Here are two alternative ASX dividend stocks

Let’s unearth some other passive income opportunities.

Read more »

A person sitting at a desk smiling and looking at a computer.
Opinions

What I plan to do if the US election causes an ASX stock market sell-off

This could be a dramatic US election. Here’s how I’m approaching it.

Read more »

Sad shopper sitting on a sofa with shopping bags.
Opinions

Is the Wesfarmers share price a buy? Here's my view

Is the Bunnings owner a buy at this lower valuation?

Read more »

piggy bank at end of winding road
Opinions

3 ASX shares I think are a safe buy in November

We look at three ASX blue chips that have proven themselves to be high-quality investments.

Read more »

A father helps his son look through binoculars during a family holiday or day out in the city.
Opinions

Up 190% in a year, why I think Life360 shares can keep soaring higher

This tech stock has plenty of potential.

Read more »

A man in business pants, a shirt and a tie lies in the shallows of a beautiful beach as he consults his laptop on the shore, just out of the water's reach.
Opinions

I don't care if the stock market crashes in 2024. I'm still buying ASX shares today

I get excited about the prospect of both bull markets and bear markets.

Read more »

Two funeral workers with a laptop surrounded by cofins.
Opinions

The perfect ASX shares to buy and hold forever

These stocks offer compelling long-term tailwinds in my view.

Read more »

A man looking at his laptop and thinking.
Bank Shares

Is it madness to buy CBA shares now?

Would I buy CBA shares today? Let's see.

Read more »